12714 Federal Register / Vol. 87, No. 44 / Monday, March 7, 2022 / Notices 

and analysis on the prevalence of 

COVID–19 misinformation on 

individual platforms including exactly 

how many users saw or may have been 

exposed to instances of COVID–19 

misinformation. 

b. Any aggregate data and analysis on 

how many users were exposed, were 

potentially exposed, or otherwise 

engaged with COVID–19 

misinformation. 

i. Exposure is defined as seeing 

content in newsfeeds, in search results, 

or algorithmically nominated content. 

ii. Potential exposure is the exposure 

users would have had if they could see 

all the content that is eligible to appear 

within their newsfeeds. 

iii. Engagement includes the clicking 

or viewing of content, as well as 

reacting. Sharing is the act of sharing a 

piece of pre-existing content within 

social media. 

c. Any aggregate data broken down by 

demographics on groups or populations 

who may have been differentially 

exposed to or impacted by COVID–19 

misinformation. 

4. Information about COVID–19 

misinformation policies on individual 

technology platforms. 

a. Any aggregate data and analysis of 

technology platform COVID–19 

misinformation policies including 

implementation of those policies and 

evaluations of their effectiveness. 

5. Information about sources of 

COVID–19 misinformation. 

a. Information about the major sources 

of COVID–19 misinformation associated 

with exposure. 

i. By source we mean both specific, 

public actors that are providing 

misinformation, as well as components 

of specific platforms that are driving 

exposure to information. 

6. Information about COVID–19 

misinformation from sources engaged in 

the sale of unproven COVID–19 

products or services (e.g., prescriptions 

for unapproved or unauthorized drugs, 

sales of alternative cures, or sales of 

other unapproved or unauthorized 

COVID–19 medical products), or other 

money-making models. 

Information About Impacted 

Communities 

7. Information about how COVID–19 

misinformation has impacted 

individuals and communities. 

a. Information about how COVID–19 

misinformation has impacted 

organizations that serve communities 

directly through service (e.g., libraries 

and food banks), and community-based 

organizations that are faith-based or 

provide affinity to communities (e.g., 

clubs and sororities or fraternities). 

b. Information about how COVID–19 

misinformation has impacted 

community members: Individuals and 

families. 

IV. How To Submit Your Response 

To facilitate review of your responses, 

please reference the subject of the RFI 

in your response. You may respond to 

some or all of the topic areas covered in 

the RFI, and you can suggest other 

factors or relevant questions. You may 

also include links to online material or 

interactive presentations. If including 

data sets, please make the data available 

in a downloadable, machine-readable 

format with accompanying metadata. 

Please note that this is a request for 

information (RFI) only. In accordance 

with the implementing regulations of 

the Paperwork Reduction Act of 1995 

(PRA), specifically 5 CFR 1320.3(h)(4), 

this general solicitation is exempt from 

the PRA. Facts or opinions submitted in 

response to general solicitations of 

comments from the public, published in 

the Federal Register or other 

publications, regardless of the form or 

format thereof, provided that no person 

is required to supply specific 

information pertaining to the 

commenter, other than that necessary 

for self-identification, as a condition of 

the agency’s full consideration, are not 

generally considered information 

collections and therefore not subject to 

the PRA. 

This RFI is issued solely for 

information and planning purposes; it 

does not constitute a Request for 

Proposal (RFP), applications, proposal 

abstracts, or quotations. This RFI does 

not commit the U.S. Government to 

contract for any supplies or services or 

make a grant award. Further, we are not 

seeking proposals through this RFI and 

will not accept unsolicited proposals. 

We note that not responding to this RFI 

does not preclude participation in any 

future procurement, if conducted. It is 

the responsibility of the potential 

responders to monitor this RFI 

announcement for additional 

information pertaining to this request. 

HHS may or may not choose to 

contact individual responders. Such 

communications would be for the sole 

purpose of clarifying statements in 

written responses. Contractor support 

personnel may be used to review 

responses to this RFI. Responses to this 

notice are not offers and cannot be 

accepted by the Government to form a 

binding contract or issue a grant. 

Information obtained as a result of this 

RFI may be used by the Government for 

program planning on a non-attribution 

basis. This RFI should not be construed 

as a commitment or authorization to 

incur cost for which reimbursement 

would be required or sought. All 

submissions become U.S. Government 

property; they will not be returned, and 

we may publish some of their content. 

Dated: March 2, 2022. 

Max Lesko, 

Chief of Staff, Office of the Surgeon General. 

[FR Doc. 2022–04777 Filed 3–4–22; 8:45 am] 

BILLING CODE 4150–28–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

Understanding Alzheimer’s Disease-2. 

Date: March 29, 2022. 

Time: 8:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Samuel C. Edwards, Ph.D., 

Chief, BDCN IRG, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 5210, MSC 7846, 

Bethesda, MD 20892, (301) 435–1246, 

edwardss@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Topics in 

Child and Adolescent Biobehavioral 

Development, Psychopathology, Sleep, and 

Cognitive Function. 

Date: March 30, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Benjamin G. Shapero, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3182, 

Bethesda, MD 20892, (301) 402–4786, 

shaperobg@mail.nih.gov. 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 44 / Monday, March 7, 2022 / Notices 12715 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: AIDS/HIV Member Conflict 

Application Review. 

Date: April 5, 2022. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Shan Wang, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 496–4390, 

shan.wang@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: March 2, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–04754 Filed 3–4–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism Special 

Emphasis Panel; RFA AA21–015— 

Collaborative Partnership between Research 

Centers in Minority Institutions (RCMI) and 

Alcohol Research Centers (U54 Clinical Trial 

Optional). 

Date: May 6, 2022. 

Time: 10:00 a.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Alcohol Abuse and 

Alcoholism, 6700B Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Ranga Srinivas, Ph.D., 

Chief, Extramural Project Review Branch, 

National Institute on Alcohol Abuse and 

Alcoholism, National Institutes of Health, 

6700B Rockledge Drive, Room 2114, 

Bethesda, MD 20892, (301) 451–2067, 

srinivar@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants; 

93.701, ARRA Related Biomedical Research 

and Research Support Awards., National 

Institutes of Health, HHS) 

Dated: March 1, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–04677 Filed 3–4–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the NIH Clinical Center 

Research Hospital Board. 

The meeting will be held as a virtual 

meeting and open to the public. 

Individuals who plan to view the virtual 

meeting and need special assistance or 

other reasonable accommodations to 

view the meeting should notify the 

Contact Person listed below in advance 

of the meeting. The meeting can be 

accessed from the NIH video https://

videocast.nih.gov/ and the CCRHB 

website https://ccrhb.od.nih.gov/ 

meetings.html. 

Name of Committee: NIH Clinical Center 

Research Hospital Board. 

Date: April 1, 2022. 

Time: 9:00 a.m. to 1:00 p.m. 

Agenda: Clinical Center CEO Update, 

Clinical and Safety Performance Metrics, 

Novel Coronavirus (COVID–19) Update, and 

other Business of the Board. 

Place: National Institutes of Health, 

Building 1, 9000 Rockville Pike, Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Persons: Pat Piringer, RN, MSN 

(C), National Institutes of Health Clinical 

Center, Bethesda, MD 20892, ppiringer@

cc.nih.gov, 301–402–2435, 202–460–7542 

(direct). 

Natascha Pointer, Management Analyst, 

Executive Assistant to Dr. Gilman, Office of 

the Chief Executive Officer, National 

Institutes of Health Clinical Center, Bethesda, 

MD 20892, npointer@cc.nih.gov, 301–496– 

4114, 301–402–2434 (direct). 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: March 1, 2022. 

Patricia B. Hansberger, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2022–04725 Filed 3–4–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

BRAIN Initiative: Novel Tools to Probe Cells 

and Circuits in the Brain (R01). 

Date: March 30, 2022. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Erin E. Gray, Ph.D., 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

6001 Executive Boulevard NSC 6152B, 

Bethesda, MD 20892, 301–402–8152, 

erin.gray@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants, National Institutes of Health, HHS) 


khammond on DSKJM1Z7X2PROD with NOTICES